Non-invasive test for the diagnosis of pancreatic cancer
A team of researchers from the Kobe University Graduate School of Medicine in Japan have developed a metabolomics-based approach to diagnose early-stage pancreatic cancer.1 The method uses gas chromatography coupled to mass spectrometry (GC?MS).
A team of researchers from the Kobe University Graduate School of Medicine in Japan have developed a metabolomics-based approach to diagnose early-stage pancreatic cancer.1 The method uses gas chromatography coupled to mass spectrometry (GC–MS).
Corresponding author Dr Masaru Yoshida commented: “Although surgical resection can be a curative treatment for pancreatic cancer, more than 80% of patients with pancreatic cancer have a locally advanced or metastatic tumour that is unresectable at the time of detection.” This is why scientists globally are trying to develop new methodsto detect the cancer in the earlier stages.
The team collected serum samples from 43 patients diagnosed with pancreatic cancer and 42 healthy volunteers. The analysis of the samples was challenging for the investigators. According to Yoshida, it was tough to measure several hundred metabolites in the serum samples at the same time with GC–MS.
The serum samples were compared from the two patient groups — in total, 159 metabolites were detected with 18 found to be significantly altered. The team developed and optimized the GC–MS method and selected four metabolites of interest to establish a diagnostic formula.
According to Yoshida, the novel diagnostic approach is safe and easy to apply. He told The Column that it is “expected to improve prognosis of patients diagnosed with pancreatic cancer by detecting their cancer early, when still in a resectable and curable state.”
Reference
1. T. Kobayashi et al, Cancer, Epidemiology, Biomarkers & Prevention,DOI:10.1158/1055-9965 (2013).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
